Kalil Masri
Cardiovascular Disease · Bay City, MINPI 1750332573
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,454 of the $100,410 with a category attached, or 80.1%. 18 manufacturers reported payments, led by Bayer at 53.9% of the total. Reporting peaked in 2019 at $86,222 and has fallen 99.9% since, to $95 in 2022. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 189 payments — averaging $531.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$54K
- Novartis$32K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$10K
- Abbott$2K
- Boston Scientific$1K
- Pfizer$863
- plus $1K from 12 others
Across 65 payments — averaging $2254.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$104K
- AstraZeneca$36K
- Novartis$6K
What the payments were for
- Consulting fees$1,4101%
- Speaking & faculty fees$80,45480%
- Travel & lodging$14,28814%
- Food & beverage$4,2584%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 60 | $54,143 |
| Novartis | 38 | $31,630 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $9,504 |
| Abbott | 11 | $1,562 |
| Boston Scientific | 7 | $1,483 |
| Pfizer | 5 | $863 |
| Johnson & Johnson | 19 | $364 |
| Amgen | 8 | $233 |
| Actelion Pharmaceuticals US, Inc. | 5 | $143 |
| Edwards Lifesciences | 1 | $115 |
| Terumo Medical Corporation | 1 | $107 |
| United Therapeutics Corporation | 4 | $63 |
| Abiomed | 2 | $57 |
| EKOS Corporation | 1 | $54 |
| Inari Medical, Inc. | 1 | $32 |
| Boehringer Ingelheim | 1 | $25 |
| AstraZeneca | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$53,297
- ENTRESTO$31,238
- LifeVest$9,156
- CardioMEMS HF System$1,410
- GENERAL - THERAPIES$1,323
- VYNDAQEL$700
- Edwards SAPIEN 3 Transcatheter Heart Valve$115
- XARELTO$110
How this compares
$100,410 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Bay City
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
- Herman KadoSouthfield$442K
- Douglas HorstmanshofRoyal Oak$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.